There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NuVasive (NASDAQ:NUVA) and Intellia Therapeutics (NASDAQ:NTLA) with bullish sentiments.
NuVasive (NUVA)
In a report released today, Kyle Rose from Canaccord Genuity maintained a Buy rating on NuVasive, with a price target of $75. The company’s shares opened today at $57.70.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 11.1% and a 51.3% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Smith & Nephew Snats, and Rewalk Robotics.
Currently, the analyst consensus on NuVasive is a Strong Buy with an average price target of $73.22, representing a 26.9% upside. In a report issued on October 19, Piper Jaffray also maintained a Buy rating on the stock with a $75 price target.
.
See today’s analyst top recommended stocks >>
Intellia Therapeutics (NTLA)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Intellia Therapeutics, with a price target of $57.50. The company’s shares opened today at $18.50, close to its 52-week low of $16.33.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.7% and a 45.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Applied Genetic Technologies, and Catalyst Biosciences Inc.
Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $40.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
